Safety and tolerability of the combination of simvastatin plus rifaximin in patients with decompensated cirrhosis: a multicenter, double-blind, placebo controlled randomized clinical trial.
Latest Information Update: 21 Dec 2021
Price :
$35 *
At a glance
- Drugs Rifaximin (Primary) ; Simvastatin (Primary)
- Indications Liver cirrhosis
- Focus Adverse reactions
- Acronyms LIVERHOPE
- 02 Oct 2018 Status changed from active, no longer recruiting to completed.
- 13 Apr 2018 This trial has been completed in Netherlands, according to European Clinical Trials Database.
- 19 Mar 2018 This trial has been completed in Spain, according to European Clinical Trials Database.